Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic faecal microbiota suspension
- Development stage
- Unknown
- Lead developer
- MaaT Pharma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal, Oral
01
Overview
Allogeneic faecal microbiota suspension is an investigational microbial therapy developed by Masaryk University (Masarykova Univerzita) for the treatment of Autism Spectrum Disorder (ASD). The therapy involves the transfer of a processed suspension of fecal microbiota from healthy donors into the gastrointestinal tract of the recipient. This approach is based on the gut-brain axis hypothesis, which suggests that dysbiosis in the gut microbiome contributes to the behavioral and gastrointestinal symptoms observed in individuals with ASD. By restoring microbial diversity and a healthy community of commensal bacteria, the suspension aims to modulate microbial metabolites and immune signaling, potentially improving core autistic symptoms and overall gut health. It is currently being evaluated in clinical trials to assess its safety and therapeutic efficacy in pediatric populations.
- Other names
- FMT suspensionallogeneic fecal microbiota suspensionfecal microbiota transplant
Beyond the preview
Go deeper on allogeneic faecal microbiota suspension.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic faecal microbiota suspension.